These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33504904)

  • 41. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
    Zhang Z; Lee JC; Lin L; Olivas V; Au V; LaFramboise T; Abdel-Rahman M; Wang X; Levine AD; Rho JK; Choi YJ; Choi CM; Kim SW; Jang SJ; Park YS; Kim WS; Lee DH; Lee JS; Miller VA; Arcila M; Ladanyi M; Moonsamy P; Sawyers C; Boggon TJ; Ma PC; Costa C; Taron M; Rosell R; Halmos B; Bivona TG
    Nat Genet; 2012 Jul; 44(8):852-60. PubMed ID: 22751098
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer.
    Messaritakis I; Politaki E; Kotsakis A; Dermitzaki EK; Koinis F; Lagoudaki E; Koutsopoulos A; Kallergi G; Souglakos J; Georgoulias V
    PLoS One; 2017; 12(7):e0181211. PubMed ID: 28719656
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantification of BIM mRNA in circulating tumor cells of osimertinib-treated patients with EGFR mutation-positive lung cancer.
    Isobe K; Yoshizawa T; Sekiya M; Miyoshi S; Nakamura Y; Urabe N; Isshiki T; Sakamoto S; Takai Y; Tomida T; Adachi-Akahane S; Iyoda A; Homma S; Kishi K
    Respir Investig; 2021 Jul; 59(4):535-544. PubMed ID: 33934994
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
    Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
    BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
    Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
    Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
    Ekin Z; Nart D; Savaş P; Veral A
    Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.
    Kloten V; Lampignano R; Krahn T; Schlange T
    Cells; 2019 Aug; 8(8):. PubMed ID: 31374957
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Microarray and pattern miner analysis of AXL and VIM gene networks in MDA‑MB‑231 cells.
    Natarajan S; Sumantran VN; Ranganathan M; Madheswaran S
    Mol Med Rep; 2018 Oct; 18(4):4147-4155. PubMed ID: 30132537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Silencing AXL by covalent siRNA-gelatin-antibody nanoconjugate inactivates mTOR/EMT pathway and stimulates p53 for TKI sensitization in NSCLC.
    Suresh D; Zambre A; Mukherjee S; Ghoshdastidar S; Jiang Y; Joshi T; Upendran A; Kannan R
    Nanomedicine; 2019 Aug; 20():102007. PubMed ID: 31085346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.
    Qian G; Guo J; Vallega KA; Hu C; Chen Z; Deng Y; Wang Q; Fan S; Ramalingam SS; Owonikoko TK; Wei W; Sun SY
    Mol Cancer Res; 2021 Oct; 19(10):1622-1634. PubMed ID: 34183449
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy.
    Kallergi G; Kontopodis E; Ntzifa A; Jordana-Ariza N; Karachaliou N; Pantazaka E; Charalambous HA; Psyrri A; Tsaroucha E; Boukovinas I; Koumarianou A; Hatzidaki D; Lianidou E; Georgoulias V; Rosell R; Kotsakis A
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326725
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.
    Papadaki MA; Kallergi G; Zafeiriou Z; Manouras L; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
    BMC Cancer; 2014 Sep; 14():651. PubMed ID: 25182808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice.
    Jia Y; Zhao S; Jiang T; Li X; Zhao C; Liu Y; Han R; Qiao M; Liu S; Su C; Ren S; Zhou C
    Lung Cancer; 2019 Nov; 137():85-93. PubMed ID: 31563735
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated
    Yoshimura A; Yamada T; Okuma Y; Fukuda A; Watanabe S; Nishioka N; Takeda T; Chihara Y; Takemoto S; Harada T; Hiranuma O; Shirai Y; Nishiyama A; Yano S; Goto Y; Shiotsu S; Kunimasa K; Morimoto Y; Iwasaku M; Kaneko Y; Uchino J; Kenmotsu H; Takahashi T; Takayama K
    Transl Lung Cancer Res; 2021 Aug; 10(8):3582-3593. PubMed ID: 34584858
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
    Liu YN; Tsai MF; Wu SG; Chang TH; Tsai TH; Gow CH; Chang YL; Shih JY
    Int J Cancer; 2019 Sep; 145(6):1609-1624. PubMed ID: 31162839
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
    Dall'Olio FG; Gelsomino F; Conci N; Marcolin L; De Giglio A; Grilli G; Sperandi F; Fontana F; Terracciano M; Fragomeno B; Tober N; Manferrari G; Brocchi S; Golfieri R; Fiorentino M; Ardizzoni A
    Clin Lung Cancer; 2021 Sep; 22(5):423-431. PubMed ID: 33849808
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2014 May; 50(7):1361-9. PubMed ID: 24548766
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
    Giles KM; Kalinowski FC; Candy PA; Epis MR; Zhang PM; Redfern AD; Stuart LM; Goodall GJ; Leedman PJ
    Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.